Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
Public ClinicalTrials.gov record NCT04279847. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of INCB057643 as monotherapy or combination with ruxolitinib for participants with myelofibrosis (MF) and other myeloid neoplasms.
Study identification
- NCT ID
- NCT04279847
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 140 participants
Conditions and interventions
Conditions
- Myelofibrosis
- Myelodysplastic Syndrome
- Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome
- Myeloproliferative Neoplasm
- Relapsed or Refractory Primary Myelofibrosis
- Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis)
- ET (Essential Thrombocythemia)
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 23, 2021 (Actual)
- Primary completion
- Apr 30, 2027 (Estimated)
- Completion
- Apr 30, 2027 (Estimated)
- Last update posted
- Apr 1, 2026
2021 – 2027
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama At Birmingham | Birmingham | Alabama | 35294 | — |
| University of Colorado Cancer Center | Aurora | Colorado | 80045 | — |
| University of Miami Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | — |
| Emory University-Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| University of Iowa Hospital and Clinics | Iowa City | Iowa | 52242 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Rutgers Cancer Institute of Nj | New Brunswick | New Jersey | 08901 | — |
| Nyu Langone Health - Long Island Hospital | Mineola | New York | 11501 | — |
| Nyu Langone Laura and Isaac Perlmutter Cancer Center | New York | New York | 10016 | — |
| Weill Medical College of Cornell University | New York | New York | 10021 | — |
| University of North Carolina At Chapel Hill | Chapel Hill | North Carolina | 27514 | — |
| University of Cincinnati Cancer Institute | Cincinnati | Ohio | 45267 | — |
| Ohio State University | Columbus | Ohio | 43210 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| Texas Oncology-Baylor Sammons Cancer Center | Dallas | Texas | 75246 | — |
| Md Anderson Cancer Center | Houston | Texas | 77030 | — |
| Oncology Consultants | Houston | Texas | 77030 | — |
| Huntsman Cancer Institute At University of Utah | Salt Lake City | Utah | 84112 | — |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 29 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04279847, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 1, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04279847 live on ClinicalTrials.gov.